Emerging evidence suggests that melanomas harboring ROS1 mutations may exhibit heightened sensitivity to immune checkpoint inhibitors (ICIs), including PD-1 and CTLA-4 inhibitors [76]. This evidence concerns the gene CTLA4 and melanoma.